| Revenue Growth | Pump revenue $8.7M (up 4%); Monitor revenue $8M (up 17%); Disposables $5M. |
|---|---|
| Mgmt Confidence | High confidence in 3870 pump demand; cautious on manufacturing ramp speed. |
| Demand Visibility | Record bookings for monitors and pumps; 3870 backlog growing after 300 shipments. |
| Order Book | Record Q3 bookings; comfortable backlog for Q4 across all product lines. |
| Margin Trends | Gross margin 76%; sequential improvement of 2 points from Q2 efficiencies. |
| Op. Leverage | Operating expenses declined to 43% of revenue from 46% year-over-year. |
| Pricing Power | New 3870 pump commands $25,000 ASP, a 23-25% lift over 3860. |
| Vol vs Price | Growth driven by both higher ASP and increased channel volume (quad-stacks). |
| Segment Growth | International revenue grew 45%; domestic revenue grew 9% in Q3. |
| New Clients | Secured orders from 'greenfield' facilities that previously rejected older pump models. |
| Capex & Debt | Cash at $63.3M; CapEx $0.2M; quarterly dividend declared at $0.20. |
| Commentary | Focusing on replacing 6,400 older pump channels with higher-margin quad-stack systems. |
| New Launches | Successful broad market launch of 3870 MRIV pump; expanded monitor remote capabilities. |
Growth
Revenue grew 14% YoY to $24.2M; international revenue surged 45% to $4.5M.
Outlook
Targeting $100M+ annualized run rate in Q4; 2027 revenue growth expected in upper-teens.
Risks
Management lowered full-year revenue ceiling by $2.8M, citing quality-control limits on production ramp speeds.
The company's earnings call, NASDAQ: IRMD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Iradimed Corp: key numbers
- Share price
- $84.84Close, Nov 16
- Market cap
- $1.08B
- Shares outstanding
- 12.79MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Iradimed Corp
All →Iradimed Q3 2026 Results: Net Income $6.51M, Up 16.7% YoY
For the nine months ended September 30, 2026, IRADIMED reported revenue of $66.6 million, a 9% increase over the prior year period. Net cash and cash equivalents grew to $63.3 million, while total stockholders' equity increased to $106.5 million from $94.6 million at the end of 2025.
- Key figure
- Net income $6.51M · +16.7% YoY
Iradimed Financial Results
IRADIMED reported record Q3 2026 revenue of $24.2 million, a 14% year-over-year increase driven by the launch of its new 3870 MR IV pump. The company also declared a quarterly cash dividend of $0.20 per share and updated its full-year 2026 revenue guidance to a range of $91.6 million to $93.1 million.
- Term
- Q3 2026
“We are pleased to report record revenue of $24.2 million for the third quarter, driven by the continued successful launch of our new 3870 MR IV pump. As our manufacturing team gains experience with the new platform while at the same time greatly ramping up production, we began realizing the efficiencies we anticipated with gross margin improving sequentially as expected.”
Roger Susi, President and Chief Executive Officer of Iradimed
“For the fourth quarter of 2026, we expect revenue of $25.0 million to $26.5 million, attaining a $100.0 million revenue run rate while generating GAAP diluted earnings per share of $0.53 to $0.57 and non-GAAP diluted earnings per share of $0.57 to $0.61.”
Roger Susi, President and Chief Executive Officer of Iradimed